who should take rsv vaccine

Most people do not need an RSV vaccine, but it is strongly recommended for certain higher‑risk groups: mainly adults 75+, some adults 50–74 with health problems, and pregnant people in late pregnancy, plus separate RSV antibody shots for babies.

Who should take the RSV vaccine?

Current public‑health guidance (2025–2026 season) recommends RSV vaccination for:

• Adults 75 years and older: a single RSV vaccine dose is recommended for all in this age group.

• Adults 50–74 at higher risk of severe RSV, such as those with: chronic heart or lung disease, significant immune compromise, or other serious conditions that make hospitalization more likely.

• Pregnant people: one dose of Pfizer’s Abrysvo between 32–36 weeks of pregnancy during RSV season (typically fall–winter) to protect the newborn via antibodies transferred before birth.

These are one‑time doses for now, not seasonal “every year” shots, although guidance can change as more data appear.

What about babies and toddlers?

Traditional “RSV vaccine” shots are not given directly to most babies yet; instead, they get long‑acting antibody injections that work like passive protection.

Key groups:

• All infants in their first RSV season: should be protected either by maternal RSV vaccination in pregnancy or by receiving an RSV monoclonal antibody (such as nirsevimab or newer agents like clesrovimab/enflonsia, depending on local availability).

• High‑risk toddlers 8–19 months: children with serious heart, lung, or immune problems may get an additional monoclonal antibody dose before their second RSV season.

Pediatric recommendations have shifted recently (for example, away from palivizumab and toward newer longer‑acting products), so parents are usually advised to confirm the current product and timing with their child’s clinician.

Who usually does not need it?

For now, routine RSV vaccination is not broadly recommended for:

• Healthy adults under 50 without special risk factors.

• Children who are not in high‑risk categories and have already passed their early RSV seasons, unless future guidance changes.

People who fall in a gray area (for example, a 60‑year‑old with moderate asthma, or someone living with a very fragile family member) are encouraged to discuss pros and cons with their clinician, since individual risk, local RSV activity, and vaccine availability matter.

Quick Q&A for “who should take RSV vaccine”

• “I’m 78 and otherwise healthy. Should I get it?”
  Yes: a single RSV vaccine dose is recommended for all adults 75 and older.

• “I’m 62 with COPD/heart failure. Does it apply to me?”
  Yes: adults 50–74 at increased risk (like serious lung or heart disease) are in the group recommended to receive an RSV vaccine.

• “I’m pregnant at 33 weeks in November. Do I qualify?”
  Yes: one dose of Abrysvo between 32–36 weeks in RSV season is recommended to protect the newborn, unless your obstetric provider advises otherwise.

• “My baby is due this fall. Baby or me—who gets what?”
  Typically, either you get the pregnancy RSV vaccine in late pregnancy or the baby gets a monoclonal antibody after birth; both aim to reduce severe RSV in the infant.

Bottom note: Information gathered from public forums or data available on the internet and portrayed here.